RANKL blockade prevents and treats aggressive osteosarcomas

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease

(2015) Ingo J. Diel et al.   EUROPEAN JOURNAL OF CANCER

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis

(2015) Branden S Moriarity et al.   NATURE GENETICS

RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?

(2015) Richard Cathomas et al.   ONCOLOGY

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

(2013) Peter Barrett-Lee et al.   LANCET ONCOLOGY

Genome-wide association study identifies two susceptibility loci for osteosarcoma

(2013) Sharon A Savage et al.   NATURE GENETICS

Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases

(2013) K. Ganda et al.   OSTEOPOROSIS INTERNATIONAL

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

(2012) Allan Lipton et al.   EUROPEAN JOURNAL OF CANCER

Bone histomorphometry using free and commonly available software

(2012) Kevin P Egan et al.   HISTOPATHOLOGY

Denosumab treatment for fibrous dysplasia

(2012) Alison M Boyce et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells

(2012) Alexander G. Beristain et al.   JOURNAL OF CELL SCIENCE

NF- B Signaling Participates in Both RANKL- and IL-4-Induced Macrophage Fusion: Receptor Cross-Talk Leads to Alterations in NF- B Pathways

(2011) M. Yu et al.   JOURNAL OF IMMUNOLOGY

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Matrix-embedded cells control osteoclast formation

(2011) Jinhu Xiong et al.   NATURE MEDICINE

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

(2011) Tomoki Nakashima et al.   NATURE MEDICINE

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

(2010) Paul A. Meyers et al.   CANCER

Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients

(2010) G. A. Odri et al.   CANCER RESEARCH

Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases

(2010) L. Endo-Munoz et al.   CANCER RESEARCH

Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

(2010) Dominique D. Pierroz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice

(2010) Sam D. Molyneux et al.   JOURNAL OF CLINICAL INVESTIGATION

RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma

(2010) Jun Ah Lee et al.   PEDIATRIC BLOOD & CANCER

Central control of fever and female body temperature by RANKL/RANK

(2009) Reiko Hanada et al.   NATURE

Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy

(2009) Robert S. Weinstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease

(2008) C. R. Walkley et al.   GENES & DEVELOPMENT

Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage

(2008) S. D. Berman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA